PURPOSE OF REVIEW: The review presents some information on known options for treatment of nonallergic @entity2490 (NAR) with introduction to new therapies. The merits and limitations of recent advancements in pharmacotherapy of this common problem are briefly discussed as well. RECENT FINDINGS: Intranasal corticosteroids are first-line therapy for NAR. @entity5023 and @entity2715 remain the only topical corticosteroids approved for NAR. The use of @entity24174 - another first-line option - has also been found to be effective even though NAR is a nonallergic entity by definition. Combination of @entity5023 and @entity24174 is a promising option in achieving better symptom reduction. Coadministration of intranasal corticosteroid and topical decongestants is an attractive topic that requires additional safety studies before recommending treatment. Although promising, no scientifically valid recommendation can be made for treatment of NAR with @entity2951 . Surgical options in @entity1 with refractory NAR are limited. New studies demonstrate a lack of correlation between objective outcome of radiofrequency ablation of the inferior turbinate and subjective @entity1 symptoms. SUMMARY: The heterogeneity in clinical presentation makes NAR treatment a daily challenge for otolaryngologists. The diversity of clinical studies with use of unique outcome measures limit systematic reviews which may be instrumental in providing strong recommendations.

An update regarding the treatment of nonallergic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2715 :: ('MESH:D001507', 'Chemical') :: ['beclomethasone'] @entity2951 :: ('MESH:D002211', 'Chemical') :: ['capsaicin'] @entity24174 :: ('MESH:C020976', 'Chemical') :: ['azelastine'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate', 'Fluticasone propionate']
@entity2490 :: (MESH:D012220,Disease) :: ['rhinitis']
